Gilead placed a major bet on cell therapy with its $12 billion acquisition of Kite in 2017.
To the frustration of some investors, the business took several years to ramp up. But sales have substantially grown in recent months. Gilead’s two marketed CAR-T therapies, Yescarta and Tecartus, together generated just shy of $400 million between July and September, a nearly 80% increase from the same three-month period a year prior.
